N.H. Code Admin. R. He-P 301.02

Current through Register No. 24, June 13, 2024

Section He-P 301.02 - Reportable Diseases

(a) Health care providers shall report to the department diagnosis, suspicion of diagnosis, or suspected incident involving the following, in accordance with He-P 301.03, in the following time frames:

(1) Within 24 hours following diagnosis or suspicion of diagnosis or suspected incident of:

a. Anthrax;

b. Arboviral infection; including but not limited to West Nile Virus, Eastern Equine Encephalitis Virus, Dengue, Chikungunya virus, Powassan virus, Zika virus and St. Louis Encephalitis;

c. Botulism;

d. Brucellosis;

e. Cholera;

f. Creutzfeld-Jacob disease

g. Diphtheria;

h. Haemophilus influenzae, invasive disease;

i. Hantavirus Pulmonary Syndrome;

j. Hepatitis, viral: A;

k. Measles;

l. Neisseria meningitidis, invasive disease;

m. Mumps;

n. Pertussis;

o. Psittacosis;

p. Plague;

q. Poliomyelitis;

r. Rabies in Humans or Animals;

s. Rubella, including Congenital Rubella Syndrome;

t. Tuberculosis Disease;

u. Tularemia;

v. Typhoid Fever;

w. Typhus;

x. Vibrio species including V. cholerae; and

y. Any suspect outbreak, cluster of illness, unusual occurrence of communicable disease, or other incident that may pose a threat to the public's health.

(2) Within 72 hours following diagnosis or suspicion of diagnosis of:

a. Acquired Immune Deficiency Syndrome (AIDS);

b. Acute flaccid myelitis;

c. Anaplasmosis;

d. Babesiosis;

e. Campylobacteriosis;

f. Chlamydia;

g. Coccidioidomycosis;

h. Cyclospora infection;

i. Cryptosporidiosis;

j. Ehrlichiosis;

k. Enterobacteriaceae species demonstrating resistance to carbapenem or production of a carbapenemase;

l. Escherichia coli O157 infection and other shiga toxin producing E. coli;

m. Giardiasis;

n. Gonorrhea;

o. Hepatitis, viral, newly diagnosed infections only: B, C;

p. Hepatitis, viral: positive B surface antigen in a pregnant woman;

q. HIV, including HIV exposure in infants;

r. Legionellosis;

s. Leprosy, Hansen's Disease;

t. Leptospirosis;

u. Listeriosis;

v. Lyme Disease;

w. Malaria;

x. Pneumococcal disease, invasive;

y. Psittacosis;

z. Rocky Mountain Spotted Fever;

ab. Salmonellosis;

ac. Shigellosis;

ad. Syphilis, including Congenital Syphilis Syndrome;

ae. Tetanus;

af. Toxic-Shock Syndrome (TSS), Streptococcal or Staphylococcal;

ag. Trichinosis;

ah. Varicella; and

ai. Yersiniosis.

(b) Laboratories shall report to the department any laboratory test indicative of or highly correlated with infection of the following microorganisms in accordance with He-P 301.03(h) :

(1) Within 24 hours:

a. Arboviral infection, including but not limited to West Nile Virus, Eastern Equine Encephalitis Virus, Dengue, Chikungunya virus, Powassan virus, Zika virus and St. Louis Encephalitis;

b. Bacillus anthracis;

c. Bordetella pertussis;

d. Clostridium botulinum;

e. Corynebacterium diphtheriae;

f. Francisella tularensis;

g. Haemophilus influenzae, sterile site;

h. Hantavirus;

i. Hepatitis, viral: A, E;

j. Mumps;

k. Mycobacterium tuberculosis: isolation of the organism or detection of its DNA;

l. Neisseria meningitidis, sterile site;

m. Polio;

n. Rabies;

o. Rubella;

p. Rubeola;

q. Salmonella typhii;

r. Vancomycin resistant Staphylococcus aureus (VRSA);

s. Vibrio species including V. cholerae; and

t. Yersinia pestis.

(2) Within 72 hours:

a. Anaplasmosis phagocytophilum;

b. Babesia microti;

c. Borrelia burgdorferi;

d. Brucella species;

e. Campylobacter species;

f. Chlamidophila psittaci;

g. Chlamydia trachomatis;

h. Clostridium tetani;

i. Coccidioides immitis;

j. Cryptosporidium parvum;

k. Cyclospora cayetanensis;

l. Ehrlichia species;

m. Enterobacteriaceae species demonstrating resistance to carbapenem or production of a carbapenemase;

n. Escherichia coli O157 and other shiga toxin producing E. coli;

o. Giardia species;

p. Hepatitis, viral: positive B surface antigen in a pregnant woman:

q. HIV, including HIV exposure in infants;

r. Legionella pneumophila;

s. Leptospira species;

t. Listeria monocytogenes;

u. Mycobacterium leprae;

v. Mycobacterium tuberculosis: blood assays only;

w. Neisseria gonorrhoeae;

x. Plasmodium species;

y. Rickettsia prowazekii;

z. Rickettsia rickettsii;

aa. Salmonella species other than Salmonella typhii;

ab. Shigella species;

ac. Streptococcus pneumoniae, sterile site;

ad. Treponema pallidum;

ae. Trichinella spiralis; and

af. Yersinia enterocolitica.

(c) Laboratories shall report to the department within 72 hours the results of all CD4+ lymphocyte laboratory tests.

(d) Laboratories shall report any tests indicative of HIV infection including antibody, antigen PCR based, and all viral load tests, including those with no virus detectable.

(e) Laboratories that are owned, operated, and located on the licensed premises of a hospital shall electronically report the test results listed in (b) -(d) above.

(f) Each hospital referred to in (d) and (e) above shall establish an electronic submission process and commence routine electronic reporting by December 31, 2018; and

(g) Hospitals referred to in (d) and (e) above shall format electronic submissions in accordance with guidance provided by the Department in the New Hampshire Local Implementation Guide for Electronic Laboratory Reporting using HL7 2.5.1, Version 4.0, 5/23/2016, available as noted in Appendix A.

(h) Laboratories shall submit clinical isolate material as requested by DHHS for the purpose of public health surveillance and investigation.

(i) Laboratories that are owned, operated, and located on the licensed premises of a hospital shall submit annually a hospital antibiogram report if one exists.

(j) The person in charge, or their designee, of any healthcare setting shall report to the department any investigation of suspected or actual incident of diversion of injectable medications in a health care setting within 72 hours of initiation of such investigation.

N.H. Code Admin. R. He-P 301.02

#3172, eff 1-2-86; ss by #4230, eff 2-23-87; ss by #4946, eff 10-2-90; amd by #6053, eff 6-24-95; ss by #6634, eff 11-25-97; ss by #8242, eff 12-30-04; ss by #9172, eff 6-6-08

Amended by Volume XXXVI Number 45, Filed November 10, 2016, Proposed by #12033, Effective 11/3/2016, Expires 11/3/2026.